Corient Private Wealth LP Acquires 227,947 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Corient Private Wealth increased its Edwards Lifesciences stake by 1,028.9% in the second quarter, adding 227,947 shares for a total holding valued at approximately $22.6 million. Institutional investors collectively own 79.46% of the company.
• Analysts remain broadly positive, with 17 Buy ratings and six Holds, producing a consensus “Moderate Buy” rating and a $100.27 price target. Edwards also exceeded quarterly earnings and revenue expectations, reporting $0.78 EPS and $1.74 billion in revenue.
• Expanded Medicare coverage for certain asymptomatic aortic stenosis patients could support demand for Edwards’ TAVR products. However, the stock’s valuation near 49 times earnings may leave it sensitive to profit-taking if procedure growth does not materialize quickly.

Corient Private Wealth LP boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 1,028.9% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 250,101 shares of the medical research company's stock after acquiring an additional 227,947 shares during the quarter. Corient Private Wealth LP's holdings in Edwards Lifesciences were worth $22,624,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. California State Teachers Retirement System increased its stake in Edwards Lifesciences by 9,187.8% in the 2nd quarter. California State Teachers Retirement System now owns 80,962,062 shares of the medical research company's stock worth $7,323,828,000 after buying an additional 80,090,362 shares during the period. BlackRock Inc. bought a new stake in Edwards Lifesciences during the 2nd quarter valued at about $5,318,092,000. Bank of New York Mellon Corp purchased a new stake in Edwards Lifesciences in the 2nd quarter valued at about $1,274,082,000. Norges Bank purchased a new stake in Edwards Lifesciences in the 4th quarter valued at about $803,686,000. Finally, Bank of America Corp DE bought a new position in Edwards Lifesciences in the 2nd quarter worth about $605,397,000. Institutional investors own 79.46% of the company's stock.

Analyst Ratings Changes

EW has been the topic of a number of research reports. Mizuho raised their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 15th. Wall Street Zen upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating in a report on Saturday. Piper Sandler reiterated an "overweight" rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. TD Cowen reissued a "buy" rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Finally, Evercore restated an "outperform" rating and set a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $100.27.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of Edwards Lifesciences stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the transaction, the senior vice president owned 14,868 shares in the company, valued at $1,353,880.08. The trade was a 3.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Annette Brüls sold 2,644 shares of the business's stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares of the company's stock, valued at $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 5,664 shares of company stock worth $511,918 over the last quarter. Insiders own 0.31% of the company's stock.

Edwards Lifesciences Stock Up 0.2%

Edwards Lifesciences stock opened at $84.54 on Monday. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm has a market cap of $48.68 billion, a P/E ratio of 48.59, a P/E/G ratio of 2.21 and a beta of 0.85. The business has a fifty day moving average of $89.16 and a two-hundred day moving average of $85.81. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business's revenue was up 13.6% compared to the same quarter last year. During the same period last year, the business posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences News Roundup

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: CMS expands TAVR coverage: The Centers for Medicare and Medicaid Services will extend Medicare coverage to certain patients with severe aortic stenosis who do not yet have symptoms. The broader eligible patient population could increase demand for Edwards’ TAVR valves and procedures, a particularly important growth opportunity for the company. CMS expands TAVR Medicare coverage to asymptomatic patients
• Positive Sentiment: Company welcomes the policy: Edwards said the national coverage determination should improve patient access to TAVR while reinforcing the role of multidisciplinary Heart Teams. The company also reaffirmed its 2026 financial guidance following the decision, suggesting no immediate deterioration in its outlook. Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision
• Positive Sentiment: Analysts remain bullish: Citi initiated or reiterated a Buy view, while BTIG reaffirmed its Buy rating with a $110 price target. William Blair also maintained a Buy rating, citing the expanded TAVR coverage and inclusion of asymptomatic patients. These targets imply substantial potential upside from recent trading levels. Analyst Buy Rating on Edwards Lifesciences
• Neutral Sentiment: Why the stock may still be under pressure: The reports identify no new company-specific negative catalyst. Investors may be waiting for evidence that the CMS change translates into procedure volumes and revenue, while Edwards’ relatively elevated valuation—about 49 times earnings—could make the shares sensitive to profit-taking or broader market weakness.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company's portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.